Cullgen raises $15M seed round

Cullgen Inc. said Thursday it raised $15 million in seed funding from GNI Group Ltd. The Delaware-based company is building a drug discovery platform based on ubiquitin-mediated protein degradation technology that will initially focus on cancer and potentially expand into inflammatory and autoimmune diseases...